What is Brief History of Pacira Company?

Pacira Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

What's the Story Behind Pacira's Rise?

Founded in 2006, Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals, Inc.) has carved a unique niche in the pharmaceutical world. This company's journey began with a clear mission: to revolutionize pain management. Their focus on innovative, non-opioid solutions has made them a notable player.

From its inception in Parsippany, New Jersey, Pacira's commitment to developing alternatives to opioids has been unwavering. Its flagship product, Pacira SWOT Analysis, EXPAREL, exemplifies this dedication, transforming postsurgical pain management. With a current market capitalization of approximately $1.22 billion as of June 2025, understanding the brief history of Pacira Pharmaceuticals is vital for anyone tracking the evolving landscape of pain therapeutics and the performance of Pacira stock.

The story of Pacira BioSciences, Inc. begins in 2006, when it was founded as Pacira Pharmaceuticals, Inc. The company later rebranded to Pacira BioSciences, Inc. in April 2019. The primary focus from the start was to develop innovative pharmaceutical products to address unmet needs, particularly in postsurgical pain management, with the goal of reducing reliance on opioids.

The founders of the company identified a critical problem: the widespread use of opioids for pain relief, which carried significant risks of addiction and adverse effects. Pacira's early business model revolved around developing and commercializing long-acting local anesthetics using proprietary drug delivery technologies. This approach aimed to provide effective pain management while minimizing the need for opioids.

The company's initial funding was crucial for its early development. Pacira secured approximately $85 million in three rounds from investors such as Orbimed, MPM Capital, and Sanderling Ventures. This funding supported the development of its first major product, EXPAREL (bupivacaine liposome injectable suspension), a sustained-release formulation designed to provide pain relief after surgery. To learn more about the Owners & Shareholders of Pacira, you can find more information.

Key Highlights of Pacira's Founding

Pacira Pharmaceuticals, now Pacira BioSciences, Inc., was founded in 2006 with a focus on postsurgical pain management.

• The company's initial goal was to reduce or eliminate the need for opioids in postsurgical pain relief.
• Pacira's primary product, EXPAREL, was developed as a sustained-release formulation.
• Initial funding totaled approximately $85 million from investors like Orbimed, MPM Capital, and Sanderling Ventures.

Pacira SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The early growth of Pacira Pharmaceuticals centered on the development and commercialization of EXPAREL, its flagship product. This strategic focus established EXPAREL as a crucial component of its business model, especially in the realm of postsurgical pain management. This period was marked by significant efforts to establish EXPAREL in the market and build a foundation for future growth.

EXPAREL Sales Performance

In the fourth quarter of 2024, EXPAREL net product sales reached $147.7 million, reflecting a 3% increase compared to the same period in 2023. Full-year 2024 sales for EXPAREL totaled $549.0 million, demonstrating the continued importance of this product to the company's revenue stream.

Product Portfolio Expansion

Pacira expanded its product offerings beyond EXPAREL. This included ZILRETTA, an extended-release corticosteroid injection for osteoarthritis, and iovera°, a device for drug-free pain control. These additions broadened the company's market presence and addressed different aspects of pain management.

ZILRETTA and iovera° Sales

ZILRETTA net product sales in the fourth quarter of 2024 were $33.1 million, a 15% increase year-over-year. iovera° net product sales for the same period were $6.5 million, reflecting a 7% increase. These figures indicate growing market acceptance and sales growth for these newer products.

Strategic Initiatives and Leadership Changes

The company implemented strategic initiatives to enhance market penetration. The 'No Pain' reimbursement program aimed to increase patient access to EXPAREL and iovera° in outpatient settings, targeting 18 million surgical procedures. Leadership also saw transitions, with Frank D. Lee assuming the role of CEO. In February 2024, a restructuring plan was initiated to reallocate resources and prioritize commercial readiness.

Pacira PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The history of Pacira BioSciences is marked by significant achievements, especially with its flagship product, EXPAREL. The company has consistently pushed boundaries in pain management, contributing to improved patient outcomes and solidifying its position in the pharmaceutical industry.

Pacira has consistently focused on innovation, particularly in developing non-opioid pain management solutions. A key innovation is the iovera° system, a novel device for drug-free pain control using cryoanalgesia.

EXPAREL Development

EXPAREL, a long-acting local anesthetic, has significantly impacted postsurgical pain management by reducing the need for opioids. This innovation has been a cornerstone of Pacira's success.

iovera° System

The iovera° system offers drug-free pain control using cryoanalgesia, expanding Pacira's portfolio of non-opioid pain management solutions. In January 2025, the company received FDA 510k clearance for a new iovera° SmartTip to manage chronic low back pain.

Gene Therapy Platform

The acquisition of GQ Bio Therapeutics GmbH in February 2025 brought a novel high-capacity adenovirus (HCAd) vector gene therapy platform to Pacira. This strategic move aligns with its '5x30' growth strategy, including PCRX-201, a gene therapy candidate for osteoarthritis.

Despite its successes, Pacira Pharmaceuticals faces challenges in a competitive market. The company experienced a revenue miss in Q3 2024, and ZILRETTA sales declined in Q1 2025 due to a sales force transition.

Market Competition

The pain management market is highly competitive, with emerging technologies and alternative therapies posing threats to Pacira's market share. Understanding the target market of Pacira is crucial for sustained growth.

Regulatory and Legal Challenges

Pacira operates in a heavily regulated pharmaceutical industry, facing ongoing regulatory and legal challenges. These challenges require continuous adaptation and strategic planning.

Strategic Pivots

Pacira has responded to challenges through strategic pivots, including the restructuring plan initiated in February 2024 to reallocate resources and prioritize U.S. commercial efforts. This demonstrates the company's adaptability.

Pacira Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The Pacira history includes several key milestones. Founded in 2006, the company, initially known as Pacira Pharmaceuticals, Inc., rebranded as Pacira BioSciences, Inc. in April 2019. Recent developments include the issuance of a patent for EXPAREL in December 2024, extending protection to July 2044, and FDA clearance for a new iovera° SmartTip. In January 2025, Pacira announced its '5x30' strategy, a five-year growth plan. The company also reported record revenues of $701 million for the full year 2024, and in April 2025, initiated a Phase 2 study for PCRX-201 and announced a $300 million share repurchase program.

5x30 Strategy

Pacira's '5x30' strategy aims to achieve significant growth by 2030. This includes treating over three million patients annually and achieving double-digit compounded annual revenue growth. The plan also focuses on improving gross margins and expanding the clinical pipeline.

Financial Outlook

The company anticipates strong revenue growth, with full-year 2025 revenue projected between $725 million and $765 million. This growth is fueled by initiatives like NOPAIN and the development of innovative therapies. Pacira's financial performance is key to its future.

Key Initiatives

The NOPAIN initiative is expected to drive increased EXPAREL utilization in outpatient settings. The development of PCRX-201, a gene therapy candidate, is a major focus for future growth. Data from this study will be shared at EULAR in the coming years.

Long-Term Goals

Pacira is committed to transforming pain management and reducing opioid reliance. The company's strategic initiatives and focus on innovative therapies position it for continued leadership in non-opioid pain management. The company's focus on its pipeline is essential.

Pacira Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs